Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2025
Reporting Period: Quarterly period ended June 30, 2025
This filing serves as a notification that the Company issued a press release and an earnings presentation regarding its financial results for the quarter ended June 30, 2025. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and Exhibit 99.2) and is not embedded within the text of this 8-K form.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being disclosed in the attached press release and earnings presentation but are not present in the body of this document.
Material Changes
No material changes versus the prior comparable period are detailed in this filing. The document solely announces the release of the quarterly results without summarizing the specific variances or trends.
Guidance, Outlook, and Risks
Management Commentary: The Company released an earnings presentation (Exhibit 99.2) which likely contains management commentary, guidance, and outlook, but the content of this presentation is not included in the filing text.
Risks and Contingencies: No specific risks or contingencies are described in this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net income, and cash flow figures for the quarter ended June 30, 2025.
- Examine Exhibit 99.2 (Earnings Presentation) for forward-looking guidance, operational updates, and management commentary.
- Verify the trading symbol COLL on the NASDAQ Global Select Market for any post-announcement price action.
- Confirm the date of the financial results announcement (August 7, 2025) against market news to ensure no conflicting reports exist.